Company

Five Prime is a leader in the discovery of innovative protein therapeutics.

We have developed a library of more than 5,700 human extracellular proteins, which we believe represent substantially all of the body’s medically important targets for protein therapeutics.

Building on this expertise in protein science, we have developed proprietary high-throughput protein screening technologies that we use to identify new targets for protein therapeutics in relatively short periods of time. As a result, we have built a pipeline of novel product candidates for cancer and inflammatory diseases.

Our drug discovery platform has also made us a sought-after discovery and development partner. To date we have generated over $262 million from collaborations with partners, including Bristol-Myers Squibb, GlaxoSmithKline and UCB Pharma.

Our strategy is to be opportunistic in our development programs. Pursuing clinical development of our product candidates both independently and in collaborations allows us to enhance the capital resources needed to strengthen our core technology and expand our product pipeline.